Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults

checkorphan
Learn more about:
Lipodystrophy
Related Clinical Trial
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan’s Lipodystrophy Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy Intraoperative Fluid Management of Liposuction , Cardiometry Versus Rohrich Formula The Visceral Adiposity Measurement and Observation Study Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptraâ„¢ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults

Official Title

Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy

Brief Summary

      HIV lipoatrophy is a condition marked by fat loss; it occurs in many patients taking
      antiretroviral (ARV) therapy that includes nucleoside reverse transcriptase inhibitors
      (NRTIs). Lipoatrophy may be related to mitochondrial toxicity, a condition that can damage
      the heart, nerves, muscles, kidneys, and liver, and can affect the body's ability to produce
      energy. NucleomaxX is a food supplement consisting of a sugar cane extract high in
      nucleosides, which are building blocks that may counteract the negative effects of NRTIs.
      Tenofovir disoproxil fumarate (TDF) is an NRTI that may cause less lipoatrophy than other
      drugs in its class, such as zidovudine (ZDV) or stavudine (d4T). The purpose of this study is
      to determine whether nucleoside supplementation with NucleomaxX and substitution of TDF for
      ZDV or d4T in an ARV regimen can reverse fat loss caused by mitochondrial toxicity in HIV
      infected adults.

      Study hypotheses: 1) The substitution of TDF for d4T or ZDV in patients with HIV lipoatrophy
      will result in an increase in mitochondrial DNA content in fat, skeletal muscle, and
      peripheral blood mononuclear cells (PBMCs), which in turn will lead to an improvement in
      mitochondrial function as assessed by electron transport chain (ETC) and oxidative
      phosphorylation pathway (OXPHOS) activity. The latter should lead to a decrease in fat
      apoptosis and in mitochondrial and lipid oxidative damage biomarkers. 2) Supplementation with
      uridine (via NucleomaxX) will increase mtDNA content in adipose tissue and increase body fat
      content.

Detailed Description

      NRTIs are an important part of many ARV regimens used to treat HIV infected patients;
      however, the relationship between NRTI-induced mitochondrial dysfunction and lipoatrophy is
      still unclear and requires additional research. Additionally, the relationship between the
      gain in dual-energy x-ray absorptiometry (DEXA)-measured limb fat and mitochondrial DNA
      (mtDNA) content, mitochondrial function, fat apoptosis, and oxidative damage will also be
      examined in this study.

      Patients will participate in this study for 48 weeks. Participants will be randomly assigned
      to one of two groups. Group 1 patients will receive NucleomaxX every other day. Group 2
      patients will substitute TDF for ZDV or d4T every day in their current stable NRTI-containing
      ARV regimen. NucleomaxX will be provided to Group 1 patients, but TDF or any other ARV will
      not be provided by this study.

      There will be 10 study visits, which will occur at study entry and Weeks 2, 4, 8, 12, 18, 24,
      30, 36, and 48. Blood collection will occur at all visits. Additionally, urine collection,
      DEXA scans, and fat biopsies will be done at study entry and Weeks 24 and 48.

Study Phase

Phase 2

Study Type

Interventional

Primary Outcome

Change in Fat mtDNA Content

Secondary Outcome

 Change in Limb Fat

Condition

HIV Infections

Intervention

NucleomaxX

Study Arms / Comparison Groups

 uridine supplementation
Description:  NucleomaxX 36 grams TID every other day

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

50

Start Date

April 2005

Completion Date

October 2008

Primary Completion Date

October 2008

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosis of HIV lipoatrophy

          -  Receiving a stable stavudine- or zidovudine-containing ARV regimen

          -  HIV-1 RNA viral load less than 50 copies/ml

        Exclusion Criteria:

          -  Coagulopathies or other bleeding disorders

          -  Diabetes requiring medication

          -  Creatinine clearance less than 50 ml/min

          -  Pregnancy or breastfeeding

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Grace A. McComsey, MD, ,

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT00119379

Organization ID

1R01AI060484-01A2B

Secondary IDs

R01AI060484

Responsible Party

Principal Investigator

Study Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Study Sponsor

Grace A. McComsey, MD, Principal Investigator, Case Western Reserve University

Verification Date

May 2017